“Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials”, J of Skin, vol. 6, no. 6, p. s66, Nov. 2022, doi: 10.25251/skin.6.supp.66.